This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Drug Therapy, Other  • Alert me on articles by topic

Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry

Bruce M. Psaty, MD, PhD; Drummond Rennie, MD

JAMA. 2006;295:2787-2790.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Large long-term clinical trials have helped to define first-line drug therapies for conditions such as high blood pressure.¹ Physician adherence to evidence-based guidelines, however, has been modest at best,² and the causes remain unclear. In a study of antihypertensive drug use in 10 countries, Fretheim and Oxman³ characterized the international variation in prescribing patterns. The prescription of thiazides, for instance, was 4-fold higher in the United Kingdom than in Norway, and conversely, the prescription of -blockers was 4-fold higher in Norway than in the United Kingdom. The authors hypothesized that these international differences were related in part to the promotion of more expensive drugs in Norway through "seeding trials," which have been described as "thinly veiled attempts to entice doctors to prescribe a new drug being marketed by the company."⁴

In this issue of JAMA, Andersen and colleagues⁵ report the findings . . . [Full Text of this Article]

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (Dr Psaty) and Institute for Health Policy Studies, University of California, San Francisco (Dr Rennie). Dr Rennie is also Deputy Editor, JAMA.

RELATED ARTICLE

How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug Preferences
, , and
JAMA. ;295():2759-2764.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

ADVANTAGE: Science First, Marketing Second
Edelman
ANN INTERN MED 2008;149:773-773.
FULL TEXT  

The ADVANTAGE Seeding Trial: A Review of Internal Documents
Hill et al.
ANN INTERN MED 2008;149:251-258.
ABSTRACT | FULL TEXT  

Seeding Trials: Just Say "No"
Sox and Rennie
ANN INTERN MED 2008;149:279-280.
FULL TEXT